Cargando…

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

SIMPLE SUMMARY: High-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a standard treatment in patients with newly diagnosed multiple myeloma (MM). At relapse, salvage HDCT/ASCT is a treatment option in patients with sufficient benefit from frontline HDCT/ASCT, but no evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Baertsch, Marc-Andrea, Fougereau, Mathilde, Hielscher, Thomas, Sauer, Sandra, Breitkreutz, Iris, Jordan, Karin, Müller-Tidow, Carsten, Goldschmidt, Hartmut, Raab, Marc-Steffen, Hillengass, Jens, Giesen, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472377/
https://www.ncbi.nlm.nih.gov/pubmed/34572934
http://dx.doi.org/10.3390/cancers13184706
_version_ 1784574713128812544
author Baertsch, Marc-Andrea
Fougereau, Mathilde
Hielscher, Thomas
Sauer, Sandra
Breitkreutz, Iris
Jordan, Karin
Müller-Tidow, Carsten
Goldschmidt, Hartmut
Raab, Marc-Steffen
Hillengass, Jens
Giesen, Nicola
author_facet Baertsch, Marc-Andrea
Fougereau, Mathilde
Hielscher, Thomas
Sauer, Sandra
Breitkreutz, Iris
Jordan, Karin
Müller-Tidow, Carsten
Goldschmidt, Hartmut
Raab, Marc-Steffen
Hillengass, Jens
Giesen, Nicola
author_sort Baertsch, Marc-Andrea
collection PubMed
description SIMPLE SUMMARY: High-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a standard treatment in patients with newly diagnosed multiple myeloma (MM). At relapse, salvage HDCT/ASCT is a treatment option in patients with sufficient benefit from frontline HDCT/ASCT, but no evidence is currently available regarding its role in the era of triplet regimens combining the most active drug classes for relapsed MM. To evaluate the outcome after salvage HDCT/ASCT following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRD) and to identify prognostic factors, we conducted a retrospective analysis of patients that had previously undergone frontline HDCT/ASCT. We found that deep remissions achieved with KRd followed by salvage autologous transplantation were associated with favorable PFS and were enhanced by maintenance treatment. Salvage autologous transplantation after state-of-the-art triplet re-induction was a safe and effective strategy for RRMM patients that may offer the chance to avoid refractoriness to multiple novel agents at the next relapse. ABSTRACT: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively report on 44 patients receiving salvage HDCT/ASCT following re-induction with carfilzomib/lenalidomide/dexamethasone (KRd). All patients received frontline HDCT/ASCT with median time to progression (TTP1) of 2.9 (1.2–13.5) years, enabling paired comparison of frontline and salvage HDCT/ASCT. After re-induction and before salvage transplant, 25/44 patients (57%) attained ≥ very good partial response (VGPR), which increased to 34/44 (77%) at best response after salvage HDCT/ASCT. Median progression-free survival (PFS) was 23.3 months from salvage HDCT/ASCT. Patients with ≥ VGPR at the time of salvage HDCT/ASCT and those receiving maintenance treatment post salvage HDCT/ASCT had significantly superior PFS (hazard ratio (HR) 0.19, p = 0.001 and HR 0.20, p = 0.009). In patients achieving at least an equal depth of response before salvage HDCT/ASCT as before frontline HDCT/ASCT, PFS after salvage HDCT/ASCT was comparable to the frontline situation (p = 0.3). This is the first report of state-of-the-art triplet re-induction and salvage HDCT/ASCT for RRMM after frontline transplantation. Deep remissions achieved with KRd translate into prolonged PFS following salvage HDCT/ASCT and are enhanced by maintenance treatment.
format Online
Article
Text
id pubmed-8472377
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84723772021-09-28 Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma Baertsch, Marc-Andrea Fougereau, Mathilde Hielscher, Thomas Sauer, Sandra Breitkreutz, Iris Jordan, Karin Müller-Tidow, Carsten Goldschmidt, Hartmut Raab, Marc-Steffen Hillengass, Jens Giesen, Nicola Cancers (Basel) Article SIMPLE SUMMARY: High-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a standard treatment in patients with newly diagnosed multiple myeloma (MM). At relapse, salvage HDCT/ASCT is a treatment option in patients with sufficient benefit from frontline HDCT/ASCT, but no evidence is currently available regarding its role in the era of triplet regimens combining the most active drug classes for relapsed MM. To evaluate the outcome after salvage HDCT/ASCT following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRD) and to identify prognostic factors, we conducted a retrospective analysis of patients that had previously undergone frontline HDCT/ASCT. We found that deep remissions achieved with KRd followed by salvage autologous transplantation were associated with favorable PFS and were enhanced by maintenance treatment. Salvage autologous transplantation after state-of-the-art triplet re-induction was a safe and effective strategy for RRMM patients that may offer the chance to avoid refractoriness to multiple novel agents at the next relapse. ABSTRACT: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively report on 44 patients receiving salvage HDCT/ASCT following re-induction with carfilzomib/lenalidomide/dexamethasone (KRd). All patients received frontline HDCT/ASCT with median time to progression (TTP1) of 2.9 (1.2–13.5) years, enabling paired comparison of frontline and salvage HDCT/ASCT. After re-induction and before salvage transplant, 25/44 patients (57%) attained ≥ very good partial response (VGPR), which increased to 34/44 (77%) at best response after salvage HDCT/ASCT. Median progression-free survival (PFS) was 23.3 months from salvage HDCT/ASCT. Patients with ≥ VGPR at the time of salvage HDCT/ASCT and those receiving maintenance treatment post salvage HDCT/ASCT had significantly superior PFS (hazard ratio (HR) 0.19, p = 0.001 and HR 0.20, p = 0.009). In patients achieving at least an equal depth of response before salvage HDCT/ASCT as before frontline HDCT/ASCT, PFS after salvage HDCT/ASCT was comparable to the frontline situation (p = 0.3). This is the first report of state-of-the-art triplet re-induction and salvage HDCT/ASCT for RRMM after frontline transplantation. Deep remissions achieved with KRd translate into prolonged PFS following salvage HDCT/ASCT and are enhanced by maintenance treatment. MDPI 2021-09-20 /pmc/articles/PMC8472377/ /pubmed/34572934 http://dx.doi.org/10.3390/cancers13184706 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Baertsch, Marc-Andrea
Fougereau, Mathilde
Hielscher, Thomas
Sauer, Sandra
Breitkreutz, Iris
Jordan, Karin
Müller-Tidow, Carsten
Goldschmidt, Hartmut
Raab, Marc-Steffen
Hillengass, Jens
Giesen, Nicola
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
title Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
title_full Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
title_fullStr Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
title_full_unstemmed Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
title_short Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
title_sort carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472377/
https://www.ncbi.nlm.nih.gov/pubmed/34572934
http://dx.doi.org/10.3390/cancers13184706
work_keys_str_mv AT baertschmarcandrea carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT fougereaumathilde carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT hielscherthomas carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT sauersandra carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT breitkreutziris carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT jordankarin carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT mullertidowcarsten carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT goldschmidthartmut carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT raabmarcsteffen carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT hillengassjens carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma
AT giesennicola carfilzomiblenalidomideanddexamethasonefollowedbysalvageautologousstemcelltransplantwithorwithoutmaintenanceforrelapsedorrefractorymultiplemyeloma